CDK5 and prostate cancer: p35 and Cdk5 are also upregulated in prostate cancer and prostate cancer cell lines and Cdk5 activity has previously been shown to contribute to prostate cancer cell motility.34 These findings suggest, therefore, that the drebrin/EB3 pathway as a whole is dysregulated in prostate cancer.